LncRNA TROJAN promotes proliferation and resistance to CDK4/6 inhibitor via CDK2 transcriptional activation in ER+ breast cancer

LncRNA TROJAN promotes proliferation and resistance to CDK4/6 inhibitor via CDK2 transcriptional activation in ER+ breast cancer

Abstract Background Estrogen receptor-positive (ER+) breast cancers represent approximately two-thirds of all breast cancers and have a sustained risk of late disease recurrence. Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors have shown significant efficacy in ER+ breast cancer. However, their...

Full description

Bibliographic Details
Main Authors: Xi Jin, Li-Ping Ge, Da-Qiang Li, Zhi-Ming Shao, Gen-Hong Di, Xiao-En Xu, Yi-Zhou Jiang
Format: Article
Language:English
Published: BMC 2020-05-01
Series:Molecular Cancer
Subjects:
Breast cancer
lncRNA TROJAN
CDK4/6 inhibitor
Online Access:http://link.springer.com/article/10.1186/s12943-020-01210-9

Internet

http://link.springer.com/article/10.1186/s12943-020-01210-9

Similar Items